Specialized research organization in real-world data.
We transform health data into scientific arguments for the pharmaceutical industry, medtechs, academic research, and health authorities.
A multidisciplinary team covering the entire real-world data value chain, from collection to evidence.
Observational studies on SNDS and hospital EDS, primary care, or pharmacy data. Phenotyping algorithms, survival analyses, causal modelling, and retrospective cohorts.
Learn moreSecure ETL pipelines, SNDS extraction and linearization (Victoria pipeline), machine learning models, and clinical natural language processing.
Learn moreLargest private portfolio of CNIL-authorized EDS in France. CESREES submissions, reference methodologies MR-004 / MR-006, GDPR governance, and DPO support.
Learn moreBurden of disease studies, budget impact models, cost-effectiveness analyses, and support for HAS/CEPS submissions, anchored in real French consumption data.
Learn moreSeven CNIL-authorized health data sources, covering primary and hospital care, pharmacy, cardiology, urology, pulmonology, and gynaecology. 6 EDS are natively linked to SNDS to enrich patient journeys.
From one-off studies to continuous data flows, we adapt our approach to your operational and regulatory challenges.
Complete pharmacoepidemiological study on SNDS. Protocol, extraction, analysis, and publication-ready report.
Simplified access to our specialized EDS (CardioHub, Colibri, DataMesh, SOG Health, THIN).
Your own health data warehouse built and hosted by Clinityx. NIS + SNDS linkage.
Isolated analytical environment, CNIL-compliant by design. Bring your own data.
31 monthly pharmacy dispensing observatories. 85% of pharmacies, 13 therapeutic areas, 20+ subscribed laboratories.
Access to national PMSI data (via ATIH, MR-006) or eSND (via CNAM, MR-008) for industry. General population studies.
Retrospective study of 7,313 axSpA patients in France (2000–2023). Analysis of the diagnostic pathway from first primary care records. THIN database.
Retrospective cohort study of 30,122 adults with long COVID in France (2020–2022). Average annual cost of €2,443 per patient during the first year post-diagnosis.
Assessment of the incidence and prognostic impact of coronary events post-TAVI. Revascularization by angioplasty was associated with a better prognosis.
Contact our team to discuss your next project.
From feasibility to publication, we support you every step of the way.